Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financials
$16.52−0.75%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M | $15.9M | $18.1M | $17.0M | $16.4M | $13.1M | $15.1M | $14.6M | $14.9M | $13.0M | $19.9M | $34.8M |
| Gross profit | $12.6M | $9.7M | $12.6M | $11.3M | $11.5M | $8.3M | $10.4M | $10.2M | $9.2M | $7.0M | $17.7M | $28.3M |
| Gross margin | 67.2% | 60.9% | 69.9% | 66.2% | 69.9% | 63.5% | 69.0% | 69.4% | 61.6% | 53.9% | 88.7% | 81.5% |
| Operating income | -$10.0M | -$7.9M | -$2.8M | -$7.4M | -$36.5M | -$22.3M | -$23.8M | -$22.1M | -$27.8M | -$36.6M | -$19.6M | -$13.8M |
| Net income | -$2.5M | $108.4M | -$6.2M | $3.7M | $13.4M | -$12.7M | -$9.7M | -$15.0M | -$13.3M | -$17.9M | -$11.3M | -$7.1M |
| Net margin | −13.2% | 680.6% | −34.3% | 21.6% | 81.4% | −96.8% | −63.8% | −102.8% | −89.5% | −137.1% | −56.6% | −20.3% |
| Diluted EPS | $-0.08 | $2.82 | $-0.28 | $0.11 | $0.45 | $-0.48 | $-0.35 | $-0.76 | $-0.73 | $-1.04 | $-1.05 | $-0.94 |
| EBITDA | -$8.9M | -$6.6M | -$1.6M | -$6.3M | -$35.3M | -$21.1M | -$21.4M | -$21.1M | -$23.9M | -$35.4M | -$18.4M | -$12.5M |
| Operating cash flow | -$59.3M | $203.9M | -$12.5M | -$6.1M | -$27.6M | -$19.6M | -$12.9M | -$20.1M | -$21.8M | -$25.4M | -$34.9M | -$14.8M |
| Free cash flow | -$59.4M | $203.9M | -$12.5M | -$6.1M | -$27.6M | -$19.6M | -$12.9M | -$20.1M | -$21.8M | -$25.4M | -$35.0M | -$14.8M |
| Diluted shares | 31.8M | 38.4M | 22.2M | 33.1M | 29.8M | 26.5M | 28.0M | 19.7M | 18.3M | 17.2M | 10.8M | 7.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $196.6M | $255.8M | $79.4M | $86.2M | $74.4M | $91.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $39.6M | $39.4M | $52.4M | $53.4M | $53.8M | $56.4M |
| Total assets | $316.7M | $356.9M | $185.5M | $181.4M | $159.9M | $178.1M |
| Total liabilities | $110.6M | $154.5M | $123.4M | $116.2M | $122.5M | $145.6M |
| Shareholders' equity | $206.1M | $202.4M | $62.2M | $65.2M | $37.4M | $32.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology